GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

Today
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Aurobindo Pharma Ltd
Intimation of receipt of necessary approvals from US Federal Trade Commission (FTC) for the acquisition of Lannett business.
M&A ▲ Positive Development LOW RISK
📅 Filed on BSE: 19 Jun 2026, 08:24 AM IST  ·  BSE ID: 014fd9d3-a64f-49fc-be22-96b14c6c56a1
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's US subsidiary got approval from US regulators to buy the Lannett business.
🤖 AI Summary
  • Aurobindo Pharma USA Inc. received US Federal Trade Commission (FTC) approval for the Lannett business acquisition.
  • The acquisition involves Aurobindo Pharma USA Inc. acquiring 100% membership interest in Lannett Company LLC.
  • The definitive agreement for this acquisition was initially entered on July 30, 2025.
  • Aurobindo Pharma anticipates the transaction will close before the end of June 2026.
🏢 How This Affects the Company
📈
Business Impact
The US FTC approval facilitates the completion of Aurobindo Pharma's acquisition of Lannett business, expanding its US market presence. The integration of Lannett Company LLC could diversify product offerings or strengthen specific therapeutic areas for Aurobindo Pharma.
⚙️
Operational Impact
The acquisition, once closed, will integrate Lannett Company LLC's operations into Aurobindo Pharma USA Inc.'s existing structure. This involves managing new assets, supply chains, and personnel associated with Lannett.
⚠️
Risk Impact
The receipt of US FTC approval mitigates a key regulatory risk previously associated with the completion of the Lannett acquisition. However, integration risks post-acquisition remain.
👥 What This Means For Shareholders
Action Required
No action is required from shareholders based on this regulatory approval update.
👤
Who Is Affected
Shareholders are indirectly affected as the company progresses towards completing a strategic acquisition. The successful closure impacts the overall business structure and future operational scope of Aurobindo Pharma.
🔍
Management Signal
The management's update indicates active progression on strategic M&A initiatives and adherence to previously announced timelines for significant transactions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Company announcement regarding the final closure of the Lannett acquisition by end of June 2026.
Subsequent financial results for insights into initial integration of Lannett business.
Any further disclosures on the operational integration plan for Lannett Company LLC.
LOW RISK The filing reports the mitigation of a major regulatory risk for a previously announced acquisition.
💡 Investor Takeaway
Aurobindo Pharma has secured the necessary US Federal Trade Commission (FTC) approval for its acquisition of 100% membership interest in Lannett Company LLC. The company expects the transaction to close before the end of June 2026, advancing the deal first intimated on July 30, 2025.
⚖️ Strengths & Concerns

✅ Positives

  • Regulatory hurdle cleared: Receipt of US FTC approval removes a significant regulatory condition for the acquisition of Lannett business.
  • Transaction nearing completion: The company anticipates the transaction will close before the end of June 2026, indicating progress towards finalization.
📅 Company Track Record
Aurobindo Pharma previously intimated a definitive agreement on July 30, 2025, for its US subsidiary to acquire 100% of Lannett Company LLC. Separately, in April 2026, Aurobindo Pharma transferred its domestic branded formulations business to Auropharm Limited for INR 143.21 Crores.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What regulatory approval did Aurobindo Pharma receive for the Lannett acquisition?
Aurobindo Pharma received the necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.
Which entity is acquiring Lannett Company LLC?
Aurobindo Pharma USA Inc., a wholly-owned subsidiary of Aurobindo Pharma Limited, will acquire 100% of the membership interest in Lannett Company LLC.
When is the Lannett acquisition expected to close?
Aurobindo Pharma anticipates that the acquisition transaction will close before the end of June 2026.
When was the initial agreement for the Lannett acquisition announced?
The definitive agreement for the acquisition of Lannett Company LLC was initially intimated via a letter dated July 30, 2025.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.